Net revenue for the fourth quarter increased by 15.8% to SEK 1,732.9 million and operating profit (EBIT), excluding items affecting comparability for the period, amounted to SEK 66.9 million (34.3), corresponding to an adjusted EBIT margin of 3.9% (2.3%).
Fourth quarter (October 1 - December 31, 2024)
- Net revenue increased by 15.8% to 1,732.9 SEKm (1,495.9)
- Gross margin was 27.0% (27.2%)
- Operating profit (EBIT) amounted to 51.9 SEKm (34.3), corresponding to an EBIT margin of 3.0% (2.3%)
- Operating profit (EBIT) excluding items affecting comparability amounted to 66.9 SEKm (34.3), corresponding to an adjusted EBIT margin of 3.9% (2.3%)
- Items affecting comparability amounted to -15.0 SEKm (-) and referred to costs attributable to the IPO
- Profit for the period amounted to 48.8 SEKm (24.7)
- Earnings per share before and after dilution was 0.48 SEK (0.26)
- Cash flow from operating activities was 31.0 SEKm (82.2)
Full year (January 1 - December 31, 2024)
- Net revenue increased by 20.0% to 6,541.1 SEKm (5,450.2)
- Gross margin was 27.3% (26.6%)
- Operating profit (EBIT) amounted to 265.8 SEKm (113.6), corresponding to an EBIT margin of 4.1% (2.1%)
- Operating profit (EBIT) excluding items affecting comparability amounted to 289.8 SEKm (113.6), corresponding to an adjusted EBIT margin of 4.4% (2.1%)
- Items affecting comparability amounted to -24.0 SEKm (-) and referred to costs attributable to the IPO
- Profit for the year amounted to 212.0 SEKm (82.4)
- Earnings per share before and after dilution was 2.09 SEK (0.85)
- Cash flow from operating activities was 209.0 SEKm (215.8)
The Board proposes to the Annual General Meeting that no dividend should be paid to the shareholders for the 2024 financial year.
Pär Svärdson, CEO, comments:
2024 was an eventful year for Apotea - we grew by 20%, increased our profitability, and at the end of the year, Apotea was listed on the Stockholm Stock Exchange. The strong growth in the fourth quarter, as well as the overall growth for FY 2024, was driven by a high demand for purchasing prescription goods online. The prescription segment of our sales grew by 28% in the fourth quarter, and in December, we set a record by expediting nearly 20,000 prescription orders in a single day.
The result for the period January-December 2024 will be presented by Apotea's CEO, Pär Svärdson, COO & deputy CEO, Sarah Ahnström, and CFO, Johan Mårild in a webcast today at 09:30 CET. The presentation will be held in English. Link to participate in the webcast: https://apotea.events.inderes.com/q4-report-2024
If you wish to participate via teleconference please use the following link:
https://events.inderes.com/apotea/q4-report-2024/dial-in
For additional information, please contact:
Ingrid Christensson, Investor Relations, phone no: +46-729 37 95 95, email: ingrid.christensson@apotea.se
This information is information that Apotea AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person set out above, for publication on February 6, 2025, at 07:30 CET.
About Apotea
Apotea is Sweden's leading online pharmacy based on market share with the goal of becoming the largest pharmacy in Sweden and thus also in the Nordic region. With the market's widest assortment, low prices and fast deliveries, Apotea makes everyday life easier for its three million active customers. In the E-barometer customer survey 2023, Apotea topped the list of consumers' favorite e-commerce players for the sixth year in a row and almost every sixth e-commerce consumer stated Apotea as their favorite. Since 2022, the Group also operates in Norway through its Norwegian subsidiary Apotera.
